The global human immunoglobulin ph for intravenous injection covid market is anticipated to grow at a CAGR of 12.5 % during the forecast period (2022-2028). The rising prevalence of chronic lymphocytic leukemia, across the globe is propelling the market growth during the forecast period. Human immunoglobulin increases the platelets in patients with immunological thrombocytopenic purpura which helps to avoid infections in patients with B-cell chronic lymphocytic leukemia.
Click Here to Get a Free Sample Report of the Human Immunoglobulin Ph for Intravenous Injection Covid Market @ https://orionmarketreports.com/request-sample/?id=111337&submit=Request+Sample%0D%0A
The rising prevalence of disease is demanding improved diagnostic tools, which is expected to provide a lucrative growth to the market during the forecast period. For instance, the coronavirus disease (COVID-19) pandemic, which was first detected on December 31, 2019, in Wuhan, China. On March 11, 2020, the World Health Organization declared coronavirus infection (COVID-19) a pandemic. According to WHO, around 1,991,562 cases of coronavirus infection (COVID-19) were reported globally on April 16, 2020,
Get 15% Discount on Buying this Report: https://orionmarketreports.com/request-discount/?id=111337&submit=Request+Discount
Moreover, For instance, according to the National Center for Biotechnology Information in May 2020, several anti-inflammatory mechanisms of Intravenous immunoglobulin (IVIG), such as the existence of autoreactive antibodies that bind cytokines or bind to the variable domains of other antibodies, may reduce the inflammatory response in severe SARS-CoV-2 infection. For 5 days, the patients were given IVIG at a rate of 0.3–0.4 g/kg/day. Within two days of treatment, their temperature had returned to normal, and their respiratory problems had subsided which is further supporting to the market growth during the forecast period.
The North America is expected to hold the prominent share in the market during the forecast period, as COVID cases were rising during the pandemic. In April 2020, according to the World Health Organization, around 604,070 cases of coronavirus virus (COVID-19) were reported in the US.
A full report of Global Human Immunoglobulin Ph for Intravenous Injection Covid Market is available at: https://orionmarketreports.com/human-immunoglobulin-ph-for-intravenous-injection-covid-market/111337/
The market for human immunoglobulin (pH4) for intravenous injection (COVID-19) is predicted to grow due to regulatory approvals of intravenous human immunoglobulin products over the forecast period. For instance, in February 2020, according to CSL Behring, Privigen which is an immune globulin intravenous (Human),10 % Liquid, has been granted orphan-drug status by the US Food and Drug Administration (FDA) as an experimental medication in the treatment of Systemic Sclerosis (SSc). SSc is a life-threatening autoimmune disorder marked by the formation of scar tissue (fibrosis) in the skin and other organs. It affects around 100,000 persons in the US.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Disease Indication
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Baxter, Bayer AG, CSL, Grifols, S.A., Octapharma AG, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Human Immunoglobulin Ph for Intravenous Injection Covid Market Report by Segment
By Type
- IgG
- IgA
- IgM
By Disease Indication
- Covid-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- B Chronic Lymphocytic Leukemia
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
